Adimab Selected as Technology Pioneer 2011 by World Economic Forum

September 01, 2010 Lebanon, NH PDF

The World Economic Forum today announced that Adimab has been selected as a 2011 Technology Pioneer. To be selected as a World Economic Forum Technology Pioneer, a company must be involved in the development of a major technology or innovation and have the potential for long-term impact on business and society. In addition, Technology Pioneers must demonstrate visionary leadership and show the signs of being a longstanding and sustainable market leader with a commercially validated technology.

“Adimab is pleased to earn the World Economic Forum’s recognition as a Technology Pioneer. Our vision has always been to provide leading Pharma and Biotech companies with broad availability to our human antibody discovery platform,” commented Tillman Gerngross, PhD, co– founder and CEO of Adimab. “We expect to significantly and positively impact healthcare by discovering better therapeutics and reducing development timelines and costs for our expanding roster of drug development partners.”

“The speed, diversity and efficiency of Adimab’s technology enable a unique business model for a drug discovery company,” said Errik Anderson, Adimab’s COO. “Our flexible licensing model allows us to provide multiple parties with unencumbered strategic access to the world’s premier human antibody discovery platform thus fueling profitable and self-sustaining operations.”

Adimab is one of 5 companies in the life sciences sector and one of 31 companies receiving the honor overall. The identification of the World Economic Forum 2011 Technology Pioneers is the result of a rigorous selection process. The Forum received more than 330 applications from around the world which were evaluated by 68 global technology experts. The 31 Technology Pioneers 2011 will share ideas and visions for the 21st century during the World Economic Forum Annual Meeting 2011 in Davos Switzerland.

For more information about the World Economic Forum Technology Pioneers Program, please visit The World Economic Forum.

About Adimab

Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.